Literature DB >> 24164504

Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions.

Amy M Sharma1, Jack Uetrecht.   

Abstract

Drug-induced skin rashes are poorly understood idiosyncratic reactions, and current methods cannot predict their occurrence. Most idiosyncratic drug reactions are thought to be caused by chemically reactive metabolites, and the skin is a frequent site of idiosyncratic reactions; however, the skin has a very limited capacity to metabolize drugs. To balance this, the skin represents a protective barrier with a very active immune response against pathogens and other types of skin injury. Therefore its response to reactive metabolites is quite different from that of the liver. The purpose of this review is to integrate emerging findings into proposed mechanisms of drug and carcinogen metabolism in the skin that are likely responsible for rashes and other immune responses of the skin. Current evidence suggests the skin possesses significant sulfotransferase and flavin monooxygenases activities, but very low cytochromes P450 activity. However, there are skin-specific P450s that are not present in the liver. The manner in which the skin responds to neoantigens through local antigen presentation and innate immune sensing is reviewed with a focus on insights gained from the contact hypersensitivity (CHS) field. The roles of keratinocytes and Langerhans cells, and the emerging function of NOD-like receptors, are highlighted.

Entities:  

Mesh:

Year:  2013        PMID: 24164504     DOI: 10.3109/03602532.2013.848214

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  5 in total

1.  Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

Authors:  Dolly A Parasrampuria; Leslie Z Benet; Amarnath Sharma
Journal:  AAPS J       Date:  2018-03-13       Impact factor: 4.009

Review 2.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

Review 3.  Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.

Authors:  Shih-Chi Su; Wen-Hung Chung
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

4.  Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.

Authors:  Virginie Aires; Dominique Delmas; Carole Le Bachelier; Norbert Latruffe; Dimitri Schlemmer; Jean-François Benoist; Fatima Djouadi; Jean Bastin
Journal:  Orphanet J Rare Dis       Date:  2014-06-05       Impact factor: 4.123

Review 5.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).

Authors:  E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.